×
Join our live online event
How top hedge funds use news to make money
form the stock market & how ordinary people are
copying their strategies
Register now!
form the stock market & how ordinary people are
copying their strategies
No thanks
ESLA – estrella immunopharma, inc. (US:NASDAQ)
DELAYED
$
| Volume Shares | |
| 1 Day Range | |
| Volume Ratio | |
| 52 Week High | |
| 52 Week Low |
| VWAP | |
| Today’s Volatility | |
| 20 Days Volatility | |
| Open | |
| Prior Close |
1D
5D
1M
3M
YTD
1Y
3Y
1 Day
ESLA
SPY
QQQ
Swipe to see more
Main News & Impact Reports
Date
Time
Symbol
Headline
Impact
1/6
02:02 pm
esla
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
Medium
Report
Estrella Immunopharma Announces Closing of $8.0 Million Registered Direct Offering and Concurrent Private Placement
1/5
08:30 am
esla
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
Medium
Report
Estrella Immunopharma, Inc. Announces $8.0 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
12/4
08:00 am
esla
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
Medium
Report
Estrella Advances STARLIGHT-1 Trial into Phase II Following Positive DSMB Recommendation
11/3
11:24 am
esla
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
High
Report
Estrella Immunopharma (NASDAQ:ESLA) had its "buy" rating reaffirmed by analysts at D. Boral Capital. They now have a $16.00 price target on the stock.
11/3
08:00 am
esla
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
Medium
Report
Estrella Immunopharma Completes Second Dose Cohort in STARLIGHT-1 Trial of EB103 with Complete Responses in All Evaluable Patients
10/31
01:02 pm
esla
Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Low
Report
Estrella Immunopharma (NASDAQ:ESLA) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Date
Time
Symbol
Company Name
Action
%Chg
Date
Time
Action
From
To
Firm
Impact
%Chg
Date
Time
Symbol
Headline
Impact
1/16
05:08 pm
esla
Form S-1/A Estrella Immunopharma,
Low
Report
Form S-1/A Estrella Immunopharma,
1/13
05:22 pm
esla
Form 8-K Estrella Immunopharma, For: Jan 07
Medium
Report
Form 8-K Estrella Immunopharma, For: Jan 07
1/6
04:02 pm
esla
Form 8-K Estrella Immunopharma, For: Jan 05
Medium
Report
Form 8-K Estrella Immunopharma, For: Jan 05
1/6
01:56 pm
esla
Form 424B5 Estrella Immunopharma,
Medium
Report
Form 424B5 Estrella Immunopharma,
12/22
10:56 am
esla
Form S-1 Estrella Immunopharma,
Medium
Report
Form S-1 Estrella Immunopharma,
12/4
09:21 am
esla
Form 8-K Estrella Immunopharma, For: Dec 04
Medium
Report
Form 8-K Estrella Immunopharma, For: Dec 04
11/12
04:09 pm
esla
Form 10-Q Estrella Immunopharma, For: Sep 30
Medium
Report
Form 10-Q Estrella Immunopharma, For: Sep 30
11/6
05:17 pm
esla
Form 8-K Estrella Immunopharma, For: Nov 03
Medium
Report
Form 8-K Estrella Immunopharma, For: Nov 03
Stock Stats
| News Stats | |
|---|---|
| All News | |
| News Wires | |
| Media Monitoring | |
| SEC Edgar Filings | |
| Upgrades | |
| Downgrades | |
| Initiated | |
| Reiterated | |
| Last Earnings | |
| Last Earnings EPS | |
| Next Earnings | |
| Order Stats |
|---|
| Sub-Penny |
|
|
| Odd lot |
|
|
| Avg. bid-ask spread |
|
|
| Avg. bid-ask size |
|
|
| Shares at ask/bid |
|
|
| Off exchange |
|
|
Main News & Impact Reports
TOP News Gainers
TOP News Decliners
Don’t Miss Out On The Next BIG Stock Move
Never get left behind with our daily ‘Shakers & Movers’ newsletter. Discover the biggest gainer or loser in the stock market, and learn exactly WHY it moved. To find out which one caught Wall Street by surprise TODAY, sign up to our newsletter below: